Gene-Eden-VIR is Antiviral: Results of a Post Marketing Clinical
Polansky, H., Itzkovitz, E. The Center for the Biology of Chronic Disease, Rochester, NY 14620
Introduction: This paper reports the results of a post
marketing clinical study that tested the effect of Gene-Eden-VIR
on viral infections. Specifically, the study tested the effect of Gene-Eden-VIR on
the severity, duration, and frequency of symptoms associated
with the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr
Virus (EBV), Human Cytomegalovirus (HCMV), or Hepatitis C Virus
(HCV). The symptoms included abnormal Pap smear, low and high
grade cervical dysplasia, warts, blisters, cold sores, hives,
skin tabs, panic attacks, depression, kidney problems, sleeping
problems, liver problems, fever, fatigue, sore throat, swollen
lymph nodes, diarrhea, and weight loss.
Treatment: A capsule of Gene-Eden-VIR includes 100 mg of
quercetin, 150 mg of camellia sinesis extract, 50 mg of a cinnamomum
extract, 25 mg of a licorice extract, and 100 mcg of selenium.
The treatment included 1, 2, 3, or 4 capsules per day, for 2 to 54
Population: 60 infected individuals, ages 20 to 66.
Results: The participants reported no side effects from
Gene-Eden-VIR. Seventy three percent of the individuals treated with Gene-Eden-VIR
reported a decrease in their symptoms. Specifically, they report
a decrease in the severity of their symptoms (p<0.001), the
duration of their symptoms (p<0.001), the frequency of their
symptoms (p<0.001). During treatment with Gene-Eden-VIR, the
participants also reported an increase in their physical
strength (p<0.001), their energy levels (p<0.001), their
concentration (p<0.001), and their general health (p<0.001). The
participants also reported a duration effect (p<0.001), that is,
those treated with Gene-Eden-VIR for a longer time report a
larger decrease in their symptoms. The research showed no
interviewer bias, no selection bias, and a surprising response
shift. The research also showed that Gene-Eden-VIR has
therapeutic consistency under varying manufacturing conditions.
Conclusions: Our post marketing clinical study showed that Gene-Eden-VIR is a safe and
effective treatment against the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV),
Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV), or Hepatitis C Virus
Note: If you would like to read the full paper, please
send an email to the Center for the Biology of Chronic Disease
(CBCD) requesting a copy.
Click Gene-Eden-VIR to see the
website of Gene-Eden-VIR that includes information for the